Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5088555
Max Phase: Preclinical
Molecular Formula: C21H19FN4O8P2S
Molecular Weight: 568.42
Molecule Type: Unknown
Associated Items:
ID: ALA5088555
Max Phase: Preclinical
Molecular Formula: C21H19FN4O8P2S
Molecular Weight: 568.42
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1ccc(C(=O)Nc2cccc(-c3nc(NC(P(=O)(O)O)P(=O)(O)O)c4ccsc4n3)c2)cc1F
Standard InChI: InChI=1S/C21H19FN4O8P2S/c1-34-16-6-5-12(10-15(16)22)19(27)23-13-4-2-3-11(9-13)17-24-18(14-7-8-37-20(14)25-17)26-21(35(28,29)30)36(31,32)33/h2-10,21H,1H3,(H,23,27)(H,24,25,26)(H2,28,29,30)(H2,31,32,33)
Standard InChI Key: QJXLSQSTCCQBET-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 568.42 | Molecular Weight (Monoisotopic): 568.0383 | AlogP: 3.81 | #Rotatable Bonds: 8 |
Polar Surface Area: 191.20 | Molecular Species: ACID | HBA: 8 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.88 | CX Basic pKa: 4.11 | CX LogP: 1.02 | CX LogD: -1.48 |
Aromatic Rings: 4 | Heavy Atoms: 37 | QED Weighted: 0.17 | Np Likeness Score: -1.74 |
1. Lee HF, Lacbay CM, Boutin R, Matralis AN, Park J, Waller DD, Guan TL, Sebag M, Tsantrizos YS.. (2022) Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase., 65 (3.0): [PMID:35077178] [10.1021/acs.jmedchem.1c01913] |
Source(1):